University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results
Standard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing
Standard BioTools to Participate in Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.